Established in May 2017, AnLing Biomed (Suzhou) Co., Ltd. is a professional contract research organization (CRO) initiated by Center for Drug Safety Evaluation and Research of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The company focuses on preclinical research and development services for pharmaceuticals, including pharmacodynamic screening, pharmacodynamic evaluation, metabolism, safety evaluation, clinical biological sample analysis, etc. The company renders services to customers mainly including developers and/or manufacturers of innovative drugs, generic drugs and/or chemicals, with its preclinical scientific and technical strengths for chemical drugs, biologics, traditional Chinese medicine, medical devices, cellular therapy products and chemicals.
Hunan Experimental Dog Breeding and Research Base
Guangxi Non-human Primate Breeding and Research Base
AnLing Biomed (Shenzhen) Co., Ltd. was established in April 2020 with the support of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and the government of Pingshan District, Shenzhen, as a preclinical research and transformation service platform for drugs and medical devices that meets GLP standards in China and other countries. Located at Building 2, Biomedicine Innovations Industrial Park, Pingshan District, Shenzhen, the facility covers an area of nearly 10,000 square meters to carry out studies of toxicology, metabolism and pharmacodynamics. Its R&D services produce data up to the standards of NMPA, EMA OECD and US FDA applications. Experimental animals are available including rat, mouse, hamster, rabbit, guinea pig, dog, mini pig, cynomolgus monkey and sheep.
ZSHK (Hong Kong) -Hong Kong Science Park Drug Safety Evaluation Platform
ZSHK (Hong Kong) is a drug safety testing center jointly established by ZSHK Laboratories Limited and Hong Kong Science and Technology Park. It is the first facility in Hong Kong that meets GLP standards and can provide toxicology, genotoxicity, toxicokinetics, safety pharmacology, reproductive toxicology, pharmacokinetics (ADME) and other preclinical services. It is expected to be put into operation in early 2022.